Introduction {#s1}
============

Lung cancer is the leading cause of cancer-related death worldwide. In 2008, 1.61 million new cases of lung cancer were diagnosed, accounting for 12.7% of all new cases of malignant tumors [@pone.0093937-Letkova1]. Although smoking has been demonstrated as a predominant risk factor of lung cancer, only a small proportion of smokers developed lung cancer during their lifetime [@pone.0093937-Hecht1]. The individual susceptibility to lung cancer can be partially explained by genetic variation [@pone.0093937-Spitz1] and possible gene-environment interactions [@pone.0093937-Riboli1].

A lot risk factors, such as tobacco smoking, ultraviolet, and ionizing radiation, can cause the formation of bulky adducts, crosslinks, and strand breaks in DNA [@pone.0093937-Hecht1]. These DNA damages are repaired by four major DNA repair pathways, namely nucleotide excision repair (NER), base excision repair (BER), double strand break repair (DSBR) and mismatch repair (MMR) pathways [@pone.0093937-Wood1]. More than a hundred protein coding genes involved in human DNA repair system pathways have been identified and studies showed that single nucleotide polymorphisms in multiple DNA repair-related genes are associated DNA repair capacity [@pone.0093937-Mohrenweiser1], [@pone.0093937-Shields1]. Cigarette smoking caused DNA damage is mainly repaired by the NER pathway [@pone.0093937-Dip1]. A lot of studies have shown that several polymorphisms of xeroderma pigmentosum complementation group C gene (XPC), a key enzyme in the NER pathway, are associated with impaired DNA repair capacity and susceptibility to lung cancer [@pone.0093937-Letkova1], [@pone.0093937-Sakoda1]--[@pone.0093937-Liu1]. Although more than a hundred SNPs in the coding regions of XPC have been reported, two common SNPs were most investigated: the Lys939Gln (rs2228001) polymorphism in the domain interacting with TFIIH, and the Ala499Val (rs2228000) polymorphism in the domain interacting with RAD23B. Additionally, the XPC intronic poly-AT insertion/deletion polymorphism (PAT) was also associated with lung cancer risk in Caucasians [@pone.0093937-Marin1]. However, the association between XPC polymorphisms (Lys939Gln, Ala499Val, and PAT) and lung cancer risk was still inconclusive and previous meta-analyses did not fully elucidate this issue [@pone.0093937-He1], [@pone.0093937-Liu1]. Thus, we performed this update meta-analysis to provide more precise estimation of the relation between XPC polymorphisms and susceptibility to lung cancer.

Methods {#s2}
=======

Literature Searching {#s2a}
--------------------

This meta-analysis was performed and reported according to the PRISMA guideline ([Checklist S1](#pone.0093937.s004){ref-type="supplementary-material"}). A literature search was carried out using PubMed, EMBASE and China National Knowledge Infrastructure (CNKI) database up to November 2013. There were no restriction of origin or languages. Searching terms included combinations of medical subheadings and key words of "Xeroderma Pigmentosum, Complementation Group C" or "XPC", "polymorphisms, single nucleotide" or "SNP", and "neoplasm, lung" or "lung cancer". Other alternative spellings and abbreviations were also considered. The reference lists of previous meta-analyses were manually examined to identify additional relevant studies.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

Studies were selected according to the following inclusion criteria: (1) full-text published articles; (2) epidemiological association studies with a hospital-based or population-based design; (3) investigating the association between XPC polymorphisms (Lys939Gln, Ala499Val, and PAT) and lung cancer risk; (4) providing detail genotype frequencies for calculating pooled odds ratio. The exclusion criteria were as follows: (1) studies without detail genotype frequencies, which were unable to calculate odds ratio; (2) if there were multiple reports of the same study, only the one with most participants or the most recent one was included and the others were excluded. Titles and abstracts of searching results were screened and full text papers were further evaluated to confirm eligibility. Two reviewers (Bo Jin and Yu Dong) independently selected eligible studies. Disagreement between the two reviewers was settled by discussing with the third reviewer (Baohui Han).

Data Extraction {#s2c}
---------------

The following data was collected by two reviewers (Bo Jin and Yu Dong) independently using a pre-designed form: name of first author, publishing time, country where the study was conducted, genotyping methods, ethnicity, source of control, number of cases and controls, genotype frequency in cases and controls. Studies with a sample size of more than 500 participants were defined as "large"; otherwise "small". Different ethnicity descents were categorized as Asian and Caucasian. Eligible studies were defined as hospital-based (HB) and community-based (PB) according to the source of control.

Statistical Analysis {#s2d}
--------------------

The association strength between XPC polymorphisms (Lys939Gln, Ala499Val, and PAT) and cancer risks was measured by odds ratio (OR) with 95% confidence intervals (95% CI). The estimates of pooled ORs were achieved by calculating a weighted average of OR from each study. A 95% CI was used for statistical significance test and a 95% CI without 1 for OR indicating a significant increased or reduced cancer risk. Odds ratios of 5 comparison models were calculated: homozygote (AA vs. aa), heterozygote (Aa vs. aa), dominant (AAAa vs. aa), recessive (AA vs. Aaaa), and allele (A vs. a) comparison models (A, variant allele; a, wild allele; the XPC 939Gln, 499Val, and PAT -- alleles were assumed as variant alleles). subgroup analyses were performed according to (i) source of control, (ii) ethnicities, and (iii) sample size, to examine the impact of these factors on the association. To test the robustness of association and characterize possible sources of statistical heterogeneity, sensitivity analysis were carried out by excluding studies one-by-one and analyzing the homogeneity and effect size for all of rest studies.

Chi-square based Q test was used to check the statistical heterogeneity between studies, and the heterogeneity was considered significant when p\<0.10 [@pone.0093937-Lau1]. The fixed-effects model (based on Mantel-Haenszel method) and random-effects model (based on DerSimonian-Laird method) were used to pool the data from different studies. The fixed-effects model was used when there was no significant heterogeneity; otherwise, the random-effects model was applied[@pone.0093937-DerSimonian1]. Publication bias was assessed using Begg's test and Egger's test[@pone.0093937-Egger1]. HWE (Hardy-Weinberg equilibrium) was tested by Pearson's X^2^ test (P\<0.05 means deviated from HWE). All analyses were performed using Stata version 11.0 (StataCorp, College Station, TX).

Results {#s3}
=======

By searching online databases and references and related papers, 219 records were retrieved. After the primary screening of titles and abstracts, 14 full-text articles were identified [@pone.0093937-Letkova1], [@pone.0093937-Sakoda1], [@pone.0093937-Chang1], [@pone.0093937-Marin1], [@pone.0093937-RaaschouNielsen1]--[@pone.0093937-Hu2], one [@pone.0093937-Hu2] of which was excluded for the reason of duplicate reports from one study ([Figure 1](#pone-0093937-g001){ref-type="fig"}). In the study reported by Chang JS [@pone.0093937-Chang1], two separate population was included and the data were represent independently; thus, each population was treated as an independent study. Therefore, a total of 14 eligible studies were included and analyzed in this meta-analysis[@pone.0093937-Letkova1], [@pone.0093937-Sakoda1], [@pone.0093937-Chang1], [@pone.0093937-Marin1], [@pone.0093937-RaaschouNielsen1]--[@pone.0093937-Wang1], including 5647 lung cancer cases and 6908 controls.

![Flow Diagram of study selection.\
\*the two populations in Chang JS's study were treated as 2 separate studies.](pone.0093937.g001){#pone-0093937-g001}

The Lys939Gln polymorphism was investigated in 10 studies [@pone.0093937-Letkova1]--[@pone.0093937-Spitz1], [@pone.0093937-Chang1], [@pone.0093937-Liu1], [@pone.0093937-Hu1], [@pone.0093937-Vogel1], [@pone.0093937-Lee1] and most of them were performed in Caucasian population. The Ala499Val polymorphism was reported in 5 [@pone.0093937-Sakoda1], [@pone.0093937-Liu1], [@pone.0093937-Bai1], [@pone.0093937-Hu1], [@pone.0093937-Lee1]studies and 4 of them were conducted in Asian population. And 5 studies[@pone.0093937-Spitz1], [@pone.0093937-Liu1], [@pone.0093937-DerSimonian1], [@pone.0093937-Egger1], [@pone.0093937-Wang1] investigated the association between PAT polymorphism and lung cancer risk. Of the 14 eligible studies, 6 studies were hospital-based and 7 studies used PCR-RFLP method. Except the Lys939Gln polymorphism reported by Shen M[@pone.0093937-Hu1], all genotype distribution data of XPC polymorphisms were in accordance with HWE. The baseline characteristics of eligible studies were shown in [table 1](#pone-0093937-t001){ref-type="table"}.

10.1371/journal.pone.0093937.t001

###### Baseline Characteristics of Eligible Studies.

![](pone.0093937.t001){#pone-0093937-t001-1}

  Author                                      Year       Country       Ethnicity   Control    HWE    Genotyping         Polymorphisms        Cases   Controls
  ------------------------------------------ ------ ----------------- ----------- --------- ------- ------------- ------------------------- ------- ----------
  Letkova L                                   2013   Slovak Republic   Caucasian     HB       YES     PCR-RFLP            Lys939Gln           382      379
  Sakoda LC                                   2012         USA         Caucasian     CB       YES    Golden Gate     Ala499Val,Lys939Gln      744      1477
  Chang JS[a](#nt101){ref-type="table-fn"}    2011         USA         Caucasian     CB       YES    Golden Gate          Lys939Gln           368      579
  Raaschou-Nielsen O                          2009       Denmark       Caucasian     CB       YES      RT-PCR             Lys939Gln           430      790
  López-Cima MF                               2007        Spain        Caucasian     HB       YES     PCR-RFLP               PAT              516      533
  De Ruyck K                                  2007       Belgium       Caucasian     HB       YES     PCR-RFLP               PAT              110      110
  Bai Y                                       2007        China          Asian       HB       YES      TaqMan        Ala499Val,Lys939Gln     1010      1011
  Hu ZB                                       2005        China          Asian       CB       YES     PCR-RFLP       Ala499Val,Lys939Gln      320      322
  Shen M                                      2005        China          Asian       CB      No^b^     RT-PCR        Ala499Val,Lys939Gln      122      122
  Vogel U                                     2005       Denmark       Caucasian     CB       YES      RT-PCR             Lys939Gln           267      269
  Lee GY                                      2005        Korea          Asian       HB       YES     PCR-RFLP     Ala499Val,Lys939Gln,PAT    432      432
  Marín MS                                    2004        Spain        Caucasian     HB       YES     PCR-RFLP               PAT              359      375
  Wang YG                                     2003        China          Asian       CB       YES     PCR-RFLP               PAT              597      509

the two populations were treated as two separate studies; b: disagreement of HWE for Lys939Gln polymorphism; HB: hospital-based studies; CB: community-based studies.

XPC Lys939Gln Polymorphism {#s3a}
--------------------------

4030 lung cancer cases and 5336 controls were available for the analysis of XPC Lys939Gln polymorphism and the meta-analysis results were showed in [table 2](#pone-0093937-t002){ref-type="table"}. In overall analysis, no significant association of XPC Lys939Gln polymorphism with lung cancer risk was observed in any of the 5 comparison models. Sub-group analysis showed that source of controls and sample size did not alter the association. However, in the subgroup analysis according to ethnicity, we found that the homozygote Gln939Gln genotype was associated with a significantly increased risk of lung cancer in Asian population (GlnGln vs LysLys, OR = 1.229, 95% CI: 1.000--1.510; GlnGln vs LysLys/LysGln, OR = 1.257, 95% CI: 1.038--1.522; [Figure 2](#pone-0093937-g002){ref-type="fig"}), while no association was found among Caucasian population. Meta-analysis results for Lys939Gln polymorphism were shown in [Table 2](#pone-0093937-t002){ref-type="table"}. No evidence of publication bias was detected by Begg's test (P = 0.283, [Figure S1](#pone.0093937.s001){ref-type="supplementary-material"}) and Egger's test (P = 0.186).

![Forrest plot of XPC Lys939Gln polymorphism (GlnGln vs. LysLys/LysGln) by ethnicity.](pone.0093937.g002){#pone-0093937-g002}
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###### Meta-analysis results of XPC Lys939Gln polymorphism.

![](pone.0093937.t002){#pone-0093937-t002-2}

                 Homozygote Model      Heterozygote Model     Dominant Model      Recessive Model      Allele Model                                                                    
  ----------- ----------------------- -------------------- --------------------- ----------------- --------------------- ------- ----------------------- ------- --------------------- -------
  Lys939Gln                                                                                                                                                                            
  Overall       1.123(0.985--1.281)          0.222          0.994(0.908--1.087)        0.309        1.021(0.938--1.112)   0.32     1.124(0.996--1.269)    0.137   1.693(0.986--2.907)   0.227
  HB            1.068(0.871--1.309)          0.474          0.976(0.847--1.125)        0.279        0.997(0.871--1.140)   0.358    1.080(0.895--1.303)    0.366   1.018(0.926--1.120)   0.483
  CB            1.165(0.981--1.384)          0.127          1.006(0.895--1.130)        0.247        1.038(0.929--1.159)   0.228    1.157(0.988--1.356)    0.08    1.056(0.976--1.143)   0.126
  Caucasian     1.056(0.890--1.253)          0.228          1.012(0.899--1.139)        0.231        1.021(0.913--1.142)   0.207    1.042(0.890--1.220)    0.179   1.021(0.943--1.106)   0.145
  Asian        1.229(1.000--1.510)\*         0.283          0.969(0.843--1.113)        0.326        1.021(0.895--1.165)   0.362   1.257(1.038--1.522)\*   0.263   1.069(0.972--1.175)   0.385
  Large         1.097(0.959--1.256)          0.259          0.983(0.896--1.079)        0.449        1.007(0.922--1.100)   0.369    1.100(0.972--1.246)    0.225   1.028(0.966--1.095)   0.233
  Small         1.763(0.983--3.163)          0.381          1.160(0.812--1.657)        0.085        1.255(0.892--1.766)   0.25     1.693(0.986--2.907)    0.13    1.265(0.985--1.624)   0.909

OR: odds ratio; CI: confidence intervals; \*significant association.

XPC Ala499Val Polymorphism {#s3b}
--------------------------

2605 patients and 3329 controls contributed to the analysis of XPC Ala499Val polymorphism. By pooling all eligible studies, we did not find any significant association between XPC Ala499Val polymorphism and susceptibility to lung cancer (AlaVal/ValVal, OR = 1.054, 95% CI: 0.950--1.170; [Figure 3](#pone-0093937-g003){ref-type="fig"}). Further stratified analysis were performed for sources of control, ethnicity and sample size, and none of these confounding factors affected the pooled results. Meta-analysis results for Ala499Val polymorphism were shown in [Table 3](#pone-0093937-t003){ref-type="table"}.Begg's test (P = 0.462, [Figure S2](#pone.0093937.s002){ref-type="supplementary-material"}) and Egger's test (P = 0.762) suggested no evidence of publication bias.

![Forrest plot of XPC Ala499Val polymorphism (AlaVal/ValVal vs. AlaAla).](pone.0093937.g003){#pone-0093937-g003}
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###### Meta-Analysis Results of XPC Ala499Val Polymorphism.

![](pone.0093937.t003){#pone-0093937-t003-3}

                Homozygote Model     Heterozygote Model     Dominant Model      Recessive Model      Allele Model                                                                  
  ----------- --------------------- -------------------- --------------------- ----------------- --------------------- ------- --------------------- ------- --------------------- -------
  Overall      1.115(0.911--1.365)         0.558          1.043(0.936--1.163)        0.14         1.054(0.950--1.170)   0.139   1.104(0.908--1.342)   0.718   1.050(0.968--1.138)   0.273
  CB           1.120(0.826--1.521)         0.359          1.150(0.986--1.340)        0.922        1.144(0.987--1.326)   0.103   1.052(0.781--1.416)   0.658   1.096(0.975--1.231)   0.157
  HB           1.111(0.849--1.455)          0.33          0.946(0.811--1.104)        0.146        0.972(0.838--1.126)   0.814   1.145(0.884--1.483)   0.299   1.009(0.902--1.129)   0.504
  Caucasian    1.013(0.690--1.488)           NA           1.083(0.901--1.302)         NA          1.074(0.899--1.282)    NA     0.980(0.673--1.428)    NA     1.044(0.905--1.205)    NA
  Asian        1.157(0.912--1.468)         0.445          1.023(0.894--1.170)        0.083        1.044(0.917--1.187)   0.076   1.154(0.918--1.450)   0.666   1.052(0.954--1.161)   0.162
  Large        1.130(0.918--1.391)         0.436          1.050(0.940--1.173)        0.086        1.061(0.954--1.180)   0.088   1.115(0.912--1.362)   0.585   1.056(0.972--1.147)   0.193
  Small        0.893(0.379--2.106)           NA           0.893(0.512--1.557)         NA          0.893(0.529--1.506)    NA     0.942(0.416--2.132)    NA     0.925(0.623--1.372)    NA

OR: odds ratio; CI: confidence intervals; NA: not available.

XPC PAT Polymorphism {#s3c}
--------------------

The PAT polymorphism was investigated in 5 studies, including 2014 lung cancer patients and 1958 controls. Only homozygote comparison and heterozygote comparison models were conducted for PAT polymorphism. The overall analysis suggested that the PAT polymorphism was not significantly associated with lung cancer risk. Subgroup analysis according to sources of controls found no significant association either. While in Caucasian population, we found carriers of the −/− genotype were associated significantly reduced risk of lung cancer in homozygote comparison model (−/− vs +/+, OR = 0.735, 95% CI: 0.567--0.952; [Figure 4](#pone-0093937-g004){ref-type="fig"}), and the −/+ genotype was also marginally associated with reduced risk (−/+ vs ++, or = 0.786, 95% CI: 0.615--1.004). No association was observed in Asian population. In the subgroup analysis of "large" studies, results showed that the −/+ genotype reduced risk of lung cancer (−/+ vs ++, OR = 0.812, 95% CI: 0.671--0.983). Meta-analysis results for PAT polymorphism were shown in [Table 4](#pone-0093937-t004){ref-type="table"}.No evidence of publication bias was found ([Figure S3](#pone.0093937.s003){ref-type="supplementary-material"}).

![Forrest plot of XPC PAT polymorphism (−/− vs. +/+) by ethnicity.](pone.0093937.g004){#pone-0093937-g004}
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###### Meta-Analysis Results of XPC PAT Polymorphism.

![](pone.0093937.t004){#pone-0093937-t004-4}

                 Homozygote Model      Heterozygote Model                          
  ----------- ----------------------- -------------------- ----------------------- -------
  Overall       0.914(0.686--1.218)          0.081           0.842(0.700--1.013)    0.305
  HB            0.834(0.615--1.131)          0.157          0.791(0.641--0.976)\*   0.34
  CB            1.223(0.826--1.809)            NA            1.037(0.706--1.522)     NA
  Caucasian    0.735(0.567--0.952)\*         0.233           0.786(0.615--1.004)    0.188
  Asian         1.151(0.865--1.530)          0.657           0.922(0.696--1.221)    0.377
  Large         0.879(0.722--1.071)           0.06          0.812(0.671--0.983)\*   0.456
  Small         1.313(0.589--2.926)            NA            1.461(0.691--3.089)     NA

OR: odds ratio; CI: confidence intervals; NA: not available; \*significant association.

Discussion {#s4}
==========

XPC is one of the 8 key genes in the NER pathway and is involved in the damage recognition, open complex formation and reparation [@pone.0093937-Sugasawa1]. The NER pathway is primarily responsible for eliminating a wide variety of DNA lesions, and thus is an important defense mechanism against structurally unrelated DNA lesions[@pone.0093937-RaaschouNielsen1]. Previous studies have suggested that DNA adduct levels can predict lung cancer development[@pone.0093937-Bak1]. Functional SNPs in protein coding regions may alter amino acids sequence and even protein function. The XPC Lys939Gln and Ala499Val polymorphisms occur in the protein coding regions and cause amino acids substitution in functional domain, thus it is reasonable that the functional polymorphisms of XPC (Lys939Gln, Ala499Val, and PAT) will alter DNA repair capacity and susceptibility to lung cancer.

In this meta-analysis, we identified 14 eligible studies, including 5647 lung cancer cases and 6908 controls, and analyzed the relationship between XPC Lys939Gln, Ala499Val, and PAT polymorphisms and susceptibility to lung cancer. We found that the XPC Lys939Gln, Ala499Val, and PAT polymorphisms were not associated with lung cancer risk in overall population. While the XPC Gln939Gln genotype was associated with significantly increased risk of lung cancer in Asian population and in Caucasian population, the PAT −/− genotype significantly reduced lung cancer risk.

The XPC Lys939Gln polymorphism is located in the interaction domain with TFIIH. By pooling 9 eligible studies, we found the Lys939Gln polymorphism was only correlated with increased risk of lung cancer in Asians. As for the PAT polymorphism, the significantly reduced susceptibility was only observed in Caucasians. These results suggested the existence of ethnic difference, which may caused by different genetic background, environment exposure, living style and other factors. To achieve more precise correlation, future studies should take ethnic difference in to consideration. In this meta-analysis, no obvious publication bias was detected. Additionally, no significant heterogeneity was present in most comparisons, except for several subgroups.

XPC polymorphisms and cancer risk has been investigated by several meta-analyses[@pone.0093937-He1], [@pone.0093937-Liu1]. Recently, He J and colleagues[@pone.0093937-He1] performed a comprehensive meta-analysis about XPC Lys939Gln and Ala499Val polymorphisms and cancer susceptibility. Compared with He J's work, we only focused on the association of XPC polymorphisms with lung cancer, while He J and colleagues[@pone.0093937-He1] analyzed a variety of cancers, including lung cancer, breast cancer, bladder cancer, colorectal cancer, etc[@pone.0093937-He1]. On the other hand, we also analyzed the PAT polymorphism. Additionally, we identified more eligible studies and performed detailed subgroup analyses. Compared with another recent meta-analysis about XPC polymorphisms and lung cancer risk reported by Liu C et al[@pone.0093937-Liu1], we excluded the duplicate study reported by Hu Z et al[@pone.0093937-Hu2], whereas Liu and colleagues did not excluded this study. For PAT polymorphism, Liu found that compared with −/− genotype, the PAT−/+ genotype was significantly associated with reduced risk of lung cancer in Asian population[@pone.0093937-Liu1]. However, we found in Caucasian population that carriers of the PAT −/− genotype had significantly reduced susceptibility to lung cancer compared with carriers of the +/+ genotype, and no significant association was observed in Asian population. While the present meta-analysis is under review, Zhu ML [@pone.0093937-Zhu1] reported another meta-analysis about XPC polymorphism and lung cancer risk. Zhu ML and colleagues evaluated the Lys939Gln and Ala499Val polymorphisms, while they did not analyze the relationship between PAT polymorphism and lung cancer.

Limitations of this meta-analysis should also be highlighted. Smoking is a predominant risk factor of lung cancer and a common cause of DNA damage. Since meta-analysis is a method based on published studies, and collecting data from published studies would miss a lot of individual data. Without enough individual data, we could not determine the interaction between XPC polymorphisms and smoking. On the other hand, the criteria for selecting subjects in each eligible studies were also quite heterogeneous. For example, in the study of Sakoda LC[@pone.0093937-Sakoda1], both lung cancer cases and controls were selected from the β-Carotene and Retinol Efficacy Trial, and they were all at high risk of cardiovascular risk. Lee GY (24) and colleagues chosen healthy volunteers as control, while controls in the study reported by López-Cima MF (18) were patients admitted to certain hospitals with various diagnoses. The heterogeneous criteria might also lead to potential bias. Cancer is a complex process involved both genetic and environmental factors, and the exposure to environment factors was not analyzed in this meta-analysis due to limited individual data. Additionally, the number of studies for the analysis of XPC Ala499Val and PAT polymorphisms were relatively small.

To summary, in this meta-analysis we found that Gln939Gln genotype was associated with significantly increased risk of lung cancer in Asian population but not in Caucasians; the PAT −/− genotype significantly reduced susceptibility to lung cancer in Caucasian population but not in Asians; the XPC Ala499Val polymorphism was not associated with lung cancer risk. Further studies are warranted to validated these findings.
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